Correlation of Toxicity With Pharmacokinetics of Pegylated Liposomal Doxorubicin (Doxil) in Metastatic Breast Carcinoma

    September 2000 in “ Cancer ”
    Olga Lyass, Beatrice Uziely, Rami Ben‐Yosef, Dinah Tzemach, Norman I. Heshing, Michal Lotem, G Brufman, Alberto Gabizon
    TLDR Doxil's toxicity varies with dose and schedule, and pharmacokinetic guidance can optimize dosing.
    The study investigated the relationship between the toxicity and pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in patients with metastatic breast carcinoma. It aimed to understand how the drug's distribution and elimination in the body correlated with adverse effects. The research involved a cohort of patients, although the exact number was not specified in the summary. The findings suggested that certain pharmacokinetic parameters were associated with increased toxicity, indicating that monitoring these parameters could help manage side effects in patients undergoing treatment with Doxil. This study contributed to optimizing dosing strategies to minimize toxicity while maintaining therapeutic efficacy.
    Discuss this study in the Community →

    Research cited in this study

    1 / 1 results